• Hypoxia-Driven Immunometabolism in Tumor Microenvironments

  2026-06-20

  This review elucidates how hypoxia shapes immunometabolic reprogramming within the tumor microenvironment, focusing on glucose metabolism’s role in immune evasion and tumor progression. The findings clarify mechanisms underlying metabolic competition and highlight emerging therapeutic targets, with implications for designing metabolism-based interventions in cancer.

• Fluorinated CXCR4 Inhibitor A1 Surpasses AMD3100 in CRC Mode

  2026-06-19

  Khorramdelazad et al. (2025) introduce A1, a new fluorinated CXCR4 inhibitor, demonstrating superior efficacy over AMD3100 (plerixafor) in colorectal cancer models. The study combines molecular, cellular, and animal data to show that A1 more effectively blocks tumor progression and immune evasion, with implications for future targeted therapies.

• Acetylspiramycin (Spiramycin B): Mechanisms, Benchmarks & Wo

  2026-06-19

  Acetylspiramycin (Spiramycin B) is a ribosomal targeting agent with potent activity against Gram-positive and macrolide-resistant pathogens. Recent evidence highlights its lower MICs compared to classic macrolides in Mycoplasma pneumoniae resistance settings. This article details its biological rationale, protocol parameters, and limitations based on peer-reviewed and product-supplied data.

• Hydrocortisone in Tumor Microenvironment and Immune Modulati

  2026-06-18

  Explore the nuanced role of hydrocortisone, a key glucocorticoid hormone, in tumor microenvironment research and immune modulation. This article uniquely integrates mechanistic insights and advanced assay guidance beyond standard inflammation models.

• PINK1/Park2-Mediated Mitophagy as a Modulator in NAFLD

  2026-06-18

  Han et al. provide new evidence that PINK1/Park2-driven mitophagy alleviates mitochondrial dysfunction and lipid accumulation in non-alcoholic fatty liver disease (NAFLD). Their work highlights Park2 as a promising molecular target, clarifying mitophagy’s therapeutic relevance in hepatic metabolic stress.

• Indazole/Indole-Based Glucagon Receptor Antagonists for Diab

  2026-06-17

  This study introduces a novel series of indazole- and indole-based glucagon receptor antagonists, structurally inspired by MK 0893, for type 2 diabetes research. The compounds exhibit potent in vitro and in vivo activity, highlighting their promise for modulating hepatic glucose production and advancing therapeutic strategies.

• Antiarrhythmic Drugs and KCa2.X Channel Modulation in AF

  2026-06-17

  This article analyzes how established antiarrhythmic agents, including Dronedarone (Multaq), interact with small conductance calcium-activated potassium (KCa2.X) channels in the context of atrial fibrillation (AF) treatment. The reference study demonstrates that most current AF drugs, despite targeting multiple cardiac ion channels, do not meaningfully inhibit KCa2.X channels at therapeutic concentrations, highlighting a critical limitation of existing pharmacotherapies.

• Romidepsin (FK228): Catalyzing Translational Shifts in Cance

  2026-06-16

  Explore how Romidepsin (FK228) is redefining translational cancer research through the intersection of epigenetic modulation, spliceosome regulation, and innovative therapeutic strategies, with a focus on hepatocellular carcinoma and beyond.

• AZD8055: Practical Guidance for mTOR Pathway Inhibition

  2026-06-16

  AZD8055 is a highly potent, selective mTOR inhibitor designed for preclinical research requiring robust inhibition of both mTORC1 and mTORC2 complexes. It is not intended for studies seeking clinical efficacy endpoints, but is well-suited for mechanistic investigations of mTOR signaling and related cell biology.

• Chemerin in NTS Elevates Sympathetic Activity and Blood Pres

  2026-06-15

  This study uncovers chemerin's role in the caudal nucleus tractus solitarius (cNTS) in increasing sympathetic nerve activity and blood pressure via CMKLR1-mediated superoxide production. The findings delineate a specific NADPH oxidase-superoxide signaling mechanism in central cardiovascular regulation, with implications for dissecting glutamatergic contributions using receptor-selective tools.

• Difloxacin HCl: Quinolone Antimicrobial for MDR & Susceptibi

  2026-06-15

  Difloxacin HCl stands out as a quinolone antimicrobial antibiotic with unique dual action: robust in vitro antimicrobial susceptibility testing and effective multidrug resistance reversal in cancer models. This guide unpacks experimental workflows, troubleshooting, and the translational edge of APExBIO's high-purity Difloxacin HCl for researchers bridging microbiology and oncology.

• Merbromin–Trypsin Interaction: Fluorescence Quenching Mechan

  2026-06-14

  This study provides a detailed fluorimetric analysis of the interaction between Merbromin and trypsin, revealing static ground-state fluorescence quenching and quantifying binding constants under varying pH. The findings establish Merbromin as a sensitive probe for protein–ligand interaction studies, with implications for biochemical research and assay development.

• TPCA-1: Precision IKK-2 Inhibitor Workflows for Inflammation

  2026-06-13

  TPCA-1 stands out as a selective IKK-2 inhibitor, empowering researchers to dissect NF-κB signaling and inflammation with nanomolar precision. Explore validated workflows, troubleshooting strategies, and practical insights that elevate TPCA-1 beyond routine cytokine inhibition—especially in rheumatoid arthritis and cell death studies.

• Serine/Glycine-Free Diet Enhances Antitumor Immunity via PD-

  2026-06-12

  Tong et al. (2024) demonstrate that a serine/glycine-free diet can suppress colorectal cancer growth by enhancing antitumor immunity, but also uncover a compensatory immune evasion mechanism through PD-L1 lactylation. These findings provide a mechanistic basis for dietary interventions as adjuncts to immunotherapy and highlight new targets for overcoming resistance.

• Quercetin: Mechanistic Leverage for Translational Researcher

  2026-06-12

  Explore how quercetin’s dual inhibition of PI3K and NF-κB, coupled with its mitochondrial apoptosis induction, positions it as a precision tool for bridging cancer and neuroinflammation research. Drawing on recent neuroprotective findings and robust mechanistic data, this article offers translational researchers strategic guidance for designing reproducible, cross-domain workflows. Protocol parameters, competitive analysis, and an outlook on the implications for mood and cognitive therapies are provided.

452 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page